Evidence map›Paper›PMID 34734952›Full record

ReviewChemical communications (Cambridge, England)2021

From Raman to SESORRS: moving deeper into cancer detection and treatment monitoring.

Sian Sloan-Dennison, Stacey Laing, Duncan Graham, Karen Faulds

Abstract readReview
In one paragraph

Review in Chemical communications (Cambridge, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Current Trends of Raman Spectroscopy in Clinic Settings: Opportunities and Challenges.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  4. Review
  5. Plasmonic and Photothermal Properties of Silica-Capped Gold Nanoparticle Aggregates.The journal of physical chemistry. C, Nanomaterials and interfaces · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Advances in the application of Raman spectroscopy in haematological tumours.Frontiers in bioengineering and biotechnology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sian Sloan-DennisonDepartment of Pure and Applied Chemistry, Technology and Innovation Centre, University of Strathclyde, 99 George Street, Glasgow, G1 1RD, UK. karen.faulds@strath.ac.uk.ORCID http://orcid.org/0000-0003-2473-1425
Stacey LaingDepartment of Pure and Applied Chemistry, Technology and Innovation Centre, University of Strathclyde, 99 George Street, Glasgow, G1 1RD, UK. karen.faulds@strath.ac.uk.ORCID http://orcid.org/0000-0001-5781-349X
Duncan GrahamDepartment of Pure and Applied Chemistry, Technology and Innovation Centre, University of Strathclyde, 99 George Street, Glasgow, G1 1RD, UK. karen.faulds@strath.ac.uk.ORCID http://orcid.org/0000-0002-6079-2105
Karen FauldsDepartment of Pure and Applied Chemistry, Technology and Innovation Centre, University of Strathclyde, 99 George Street, Glasgow, G1 1RD, UK. karen.faulds@strath.ac.uk.ORCID http://orcid.org/0000-0002-5567-7399

Funding

Medical Research Council MR/V038303/1
6 · The paper itself

Abstract

Raman spectroscopy is a non-invasive technique that allows specific chemical information to be obtained from various types of sample. The detailed molecular information that is present in Raman spectra permits monitoring of biochemical changes that occur in diseases, such as cancer, and can be used for the early detection and diagnosis of the disease, for monitoring treatment, and to distinguish between cancerous and non-cancerous biological samples. Several techniques have been developed to enhance the capabilities of Raman spectroscopy by improving detection sensitivity, reducing imaging times and increasing the potential applicability for

Indexed as

AlkynesBiomarkers, TumorHumansHydrogen-Ion ConcentrationLipidsNanoparticlesNeoplasmsSpectrum Analysis, RamanAlkynesBiomarkers, TumorLipids

Identifiers

PMID34734952
PMCPMC8609625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.